Tibolone: A Unique Version of Hormone Replacement Therapy

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 874-881

  Swegle, John M ^a   Kelly, Michael W ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Hormone replacement therapy; Menopause; Tibolone

Indexed keywords

ANDROGEN RECEPTOR; ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYTOCHROME P450; DRUG METABOLITE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; HYDROXYPROLINE; HYDROXYSTEROID DEHYDROGENASE; LUTEINIZING HORMONE; NORETHISTERONE; OSTEOCALCIN; PROGESTERONE; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFATASE; TIBOLONE; VITAMIN D; WARFARIN;

ABDOMINAL PAIN; APOPTOSIS; BODY WEIGHT DISORDER; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; BREAST CANCER; BREAST TENDERNESS; CELL PROLIFERATION; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; EDEMA; ENDOMETRIUM ATROPHY; ENZYME INDUCTION; ENZYME INHIBITION; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYDROXYLATION; INSOMNIA; MASTALGIA; MENOPAUSAL SYNDROME; NERVOUSNESS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; SPOTTING; SWEATING; VAGINA BLEEDING; VAGINAL DRYNESS; VAGINAL PRURITUS; VAGINITIS;

BREAST NEOPLASMS; CARDIOVASCULAR SYSTEM; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; THROMBOEMBOLISM;

EID: 1942502870     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D462     Document Type: Review

References (40)

1. Tax L, Goorissen EM, Kicovic PM. Clinical profile of Org OD 14. Maturitas 1987;(suppl 1):3-13.
2. Product monograph. Livial (tibolone). Oss, Netherlands: Organon International, May 2001.
3. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-8.
4. Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23.
5. Ginsburg J, Prelevic GM. Cause of vaginal bleeding in postmenopausal women taking tibolone. Maturitas 1996;24:107-10.
6. Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351-9.
7. Vos RME, Krebbers SFM, Verhoeven CHJ, Delbressine LPC. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002;30:106-12.
8. Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001;40:165-71.
9. Bodine RVN, Harris HA, Lyttle R, Komm BS. Estrogenic effects of 7α-methly-17α-ethynylestradiol: a newly discovered tibolone metabolite. Steroids 2002;67:681-6.
10. Timmer CJ, Verheul AM, Doorstam DP. Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol 2002;54:101-6.
11. Egarter C, Sator M, Berghammer P, Huber J. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. Int J Gynecol Obstet 1999;64:281-6.
12. Mendoza N, Pison JA, Fernandez M, Sanchez MC, Malde J, Miranda JA. Prospective, randomized study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002;41:289-98.
13. Egarter C, Huber J, Leikermoser R, Haidbauer R, Pusch H, Fischl F, et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996;23:55-62.
14. Huber J, Palacios S, Berglund L, Hanggi W, Sathanandan SM, Christau S, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002;109:886-93.
15. Mendoza N, Suarez AM, Alamo F, Bartual E, Vergara F, Herruzo A. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17β-estradiol for hormonal replacement therapy in women with surgical menopause. Maturitas 2000;37:37-43.
16. Kokcu A, Cetinkaya B, Yanik F, Alper T, Malatyalioglu E. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000;36:75-80.
17. Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial) over 8 years. Maturitas 1995;21:71-6.
18. Edeveen AGH, Kloosterboes HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Min Res 2001;16:1651-7.
19. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46.
20. Berning B, Kuijk C, Kuiper JW, Coelingh Bennink HJT, Fauser BCJM. Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years of hormone replacement therapy with tibolone. Maturitas 1999;31:151-9.
21. Lindsay R, Hart DMcK, Kraszewski A. Prospective, double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J 1980;280:1207-9.
22. Berning B, Kuijk CV, Kuiper JW, Coelingh Bennink HJT, Kicovic PM, Fauser BCJM. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996;19:395-9.
23. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-26.
24. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419-22.
25. Studd J, Arnala I, Kicovic PM, Zamblera D, Kroger H, Holland N. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998; 92:574-9.
26. Bjarnason NH, Bjarnason K, Hassager C, Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 1997;20:151-5.
27. Brooke-Wavell K, Prelevic GM, Bartram C, Ginsburg J. The influence of physical activity on the response of bone mineral density to 5 years of tibolone. Maturitas 2000;35:229-35.
28. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
29. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: the principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
30. Erel CT, Elter K, Akman C, Ersavasti G, Altug A, Seyisoglu H, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998;69:870-5.
31. Colacurci N, Mele D, De Franciscis P, Costa V, Fortunato N, De Seta L. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol 1998;80:235-8.
32. Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Soderqvist G, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22.
33. Bartow SA, Pathak DR, Mettler FA, Key CR, Pike MC. Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol 1995;142:813-9.
34. Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001;40:165-71.
35. Barnes JF, Farish E, Rankin M, Hart DM. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis 2002;160:185-93.
36. Milner MH, Sinnott MM, Cooke TM, Kelly A, McGill T, Harrison RF. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol 1996;87:593-9.
37. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJT. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10-9.
38. Celik H, Ayar A, Tug N, Cikim G, Kilic N, Parmaksiz C. Effects of tibolone on plasma homocysteine levels in postmenopausal women. Fertil Steril 2002;78:347-50.
39. Ridker PM, Rifai N, Rose L, Buing JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
40. Garnero P, Jamin C, Benhamou CL, Pelissier C, Roux C. Effects of tibolone and combined 17β-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. Hum Reprod 2002;17:2748-53.